Treeline Biosciences is a Watertown, Massachusetts biotech founded in 2021 by Loxo Oncology founder Josh Bilenker and former Novartis oncology head Jeff Engelman. It pairs in-house wet-lab R&D with leading-edge computational tools to invent cancer medicines reliably and repeatedly, choosing targets by what the technology can reach rather than by therapeutic fashion. After operating largely in stealth, Treeline has raised more than $1.1 billion and moved three programs - a BCL6 degrader, a pan-KRAS inhibitor, and an EZH2 inhibitor - into Phase 1 trials. In June 2026 it agreed to go public through an all-stock reverse merger with Standard BioTools, with the combined company set to trade on Nasdaq as 'TRLN'.
Vivodyne is a biotech company that grows more than 20 types of lifelike human organ tissues in the lab, then uses robotic automation to dose, cultivate, and analyze more than 10,000 of them at a time. The vast human datasets it generates feed multimodal AI models that predict how new drugs will behave in people - before they ever reach a clinical trial. The pitch is blunt: roughly 95% of therapies that work in animal models fail in human trials, and Vivodyne wants to fix that gap with real human data instead of mice.
Medisafe is a digital health company that turns the everyday struggle of taking pills on time into a behavior-driven engagement platform. Born from a near-fatal insulin overdose in the founders' own family, it began as a free virtual pillbox app and grew into an enterprise platform - anchored by Medisafe Maestro and its Just-in-Time Interventions (JITI) engine - that pharmaceutical companies use to keep patients on therapy. With more than 13 million users worldwide and 4+ billion doses tracked, Medisafe sits at the intersection of consumer mobile health and the multibillion-dollar problem of medication non-adherence.
Vincent Ling is the Chief Business Officer of Morphocell Technologies, a Laval-based regenerative medicine company building iPSC-derived engineered tissues to treat severe organ dysfunction, starting with liver disease. A biotech and pharma veteran of three decades, he spent 12 years at Takeda's Center for External Innovation, where he identified and backed the Kariko-Weissman mRNA platform out of the University of Pennsylvania - the science that became the first COVID mRNA vaccines and earned the 2023 Nobel Prize. He has held leadership roles at Genetics Institute, Adnexus Therapeutics, and Neurotech Pharmaceuticals, and advises the Gates Foundation and academic institutions.
Anthony Costello is the CEO of Medidata Solutions, a Dassault Systèmes company, and one of clinical research technology's most seasoned architects. With nearly 30 years in the field, he started as a data manager at Genentech, co-founded two companies (Nextrials and Mytrus), and was acquired by Medidata before rising to lead it. Today he oversees over 8,000 active clinical studies globally each year, championing AI-driven trial innovation, decentralized models, and patient-centric design at the White House Clinical Trials Forum and beyond.
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy. Its Cell Shuttle - a fully automated, high-throughput platform roughly the size of a small conference room - replaces a warren of manual labs with one box that can run 16 patient batches in parallel, cutting labor and facility footprint by about 90 percent.
Medable is a Palo Alto-based digital health company building a cloud SaaS platform for decentralized and hybrid clinical trials. Its tools - eCOA+, Total Consent, Sensors, and Televisit - let pharma sponsors and CROs run studies remotely, enrolling patients in over 60 countries and 120+ languages.
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
Power is a patient-first marketplace for clinical trials. The platform helps patients discover and enroll in promising research studies, while giving sites, sponsors, and CROs an AI-driven engine to accelerate recruitment across 30,000+ active U.S. trials and 10,000+ conditions.
Shahed Jaber is the Co-Founder of Aumet Inc, MENA's largest B2B healthcare procurement marketplace. Based in Riyadh, Saudi Arabia, he previously founded UniOrders - a B2B healthcare marketplace acquired by Aumet in 2020. With a pharmacy background from the University of Jordan, Jaber has helped grow Aumet into an AI-first procurement platform serving 12,000+ pharmacies and 32 hospitals across the MENA region, processing over $1 billion in GMV and raising $21.84M in total funding.
Dan Riskin is a physician-entrepreneur, trauma surgeon, and healthcare AI executive who founded Verantos in 2015 to generate high-validity real-world evidence from messy clinical data. A serial innovator who began coding at age 5 and sold software at 12, Riskin holds an MD from Boston University and an MBA from MIT, is board-certified in four specialties, and serves as Clinical Professor of Surgery at Stanford. His prior company Health Fidelity was acquired for more than $150 million. Today, Verantos powers regulatory and reimbursement decisions for major pharmaceutical companies by turning fragmented EHR data into research-grade evidence at scale.
Dr. Siva Samy is the founder, CEO, and Chief Product Strategist of ValGenesis, the global leader in digital validation lifecycle management for the life sciences industry. He built the first platform to fully digitize and automate the pharmaceutical validation process - the compliance-critical system that ensures every drug, device, and biotech product is manufactured correctly. Under his leadership, ValGenesis has become trusted by 30 of the top 50 global life sciences companies and has raised over $40 million in funding, including a $24M investment from Morgan Stanley Expansion Capital and a $16M debt financing in 2025.
Steve Herne is the CEO of Unlearn.AI, a San Francisco-based company building AI-powered digital twin technology to transform how clinical trials are designed and run. With over 25 years of experience across pharmaceutical R&D companies including WCG, Bioclinica, and Covance, Herne joined Unlearn in May 2024 as Chief Commercial Officer before ascending to CEO in September 2024. Under his leadership, Unlearn — backed by $130M+ in venture funding including a $50M Series C led by Altimeter Capital — is pivoting from research-led to commercially-driven product delivery, with its digital twin models now EMA-qualified and adopted by major biopharma companies to reduce placebo arm sizes by up to 38% in pivotal trials.
Supreet Deshpande is Co-Founder and CEO of Synthio Labs, a Y Combinator-backed startup building clinical-grade voice AI for the life sciences industry. Drawing on his experience leading Gen AI for Life Sciences at McKinsey and analytics work at ZS Associates and JPMorgan Chase, Deshpande is solving a stubborn pharma problem: 70% of physicians never hear from a field team despite billions spent. Synthio's AI voice agents - reaching every clinician and patient with compliant, multilingual, FDA-aligned conversations - raised a $5M seed round led by Elevation Capital in November 2025 and already counts several Top 10 pharma companies as customers.
Hermann Tribukait is the co-founder and CEO of Atinary Technologies, a Lausanne- and Silicon Valley-based deeptech startup that built SDLabs — a no-code AI/ML platform compressing years of R&D into days. A Harvard-trained economist who helped coin the term 'Self-Driving Labs®' in 2017, Tribukait has channeled a career spent brokering $200M+ in global R&D partnerships into software that lets machines design experiments, learn from results, and iterate without human bias getting in the way. Atinary's tools are now used in pharma, biotech, chemicals, and climate tech, with a physical self-driving lab open in Boston since early 2026.
Yoneda Labs is building the foundation model for chemical manufacturing - think of it as the AI brain that tells chemists exactly which conditions to use to make a reaction work, before they spend months running dead-end experiments. Founded by three Cambridge graduates and backed by Khosla Ventures and Y Combinator, the company's software suite (Predict, Optimize, Analyze) compresses reaction optimization timelines from months to days. Their first named partnership with Symeres pushed cross-coupling reaction yields from ~30% to over 90%. The goal: become the universal AI layer for the $5 trillion chemical industry.